Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595723 · ClinicalTrials.gov registry record · Phase 4
Phenytoin for Memory Impairment Secondary to Megestrol
A Phase 4 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 21
- Enrollment target
NCT02595723 is a Phase 4 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 21 participants.
The verdict
NCT02595723, a Phase 4 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is designed to test if megestrol acetate induces changes in declarative memory in healthy controls and if pre-administration of phenytoin can ameliorate any induced cognitive impairments.
Interventions
- DRUG Phenytoin 200 mg capsule
- DRUG Megestrol 800 mg liquid
- DRUG Phenytoin-matched Placebo capsule
- DRUG Megestrol-matched liquid Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02595723
The ClinicalTrials.gov registry entry for NCT02595723 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Phenytoin 200 mg capsule is the first listed.
NCT02595723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02595723 about?
NCT02595723 is a clinical study titled "Phenytoin for Memory Impairment Secondary to Megestrol". This study is designed to test if megestrol acetate induces changes in declarative memory in healthy controls and if pre-administration of phenytoin can ameliorate any induced cognitive impairments.
What is the current status of trial NCT02595723?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 21 participants. The study started on 2015-07. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02595723?
The interventions under investigation include: Phenytoin 200 mg capsule (DRUG), Megestrol 800 mg liquid (DRUG), Phenytoin-matched Placebo capsule (DRUG), Megestrol-matched liquid Placebo (DRUG).
Who is sponsoring clinical trial NCT02595723?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.